CANY
TCRT icon

Caxton Associates (New York)’s Alaunos Therapeutics TCRT Stock Holding History

Caxton Associates (New York)’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,909
Closed -$180K – 647
2023
Q1 		$180K Sell
1,909
-171
-8% -$16.3K 0.03% 429
2022
Q4 		$203K Hold
2,080
– – 0.01% 381
2022
Q3 		$537K Buy
2,080
+1,409
+210% +$409K 0.07% 223
2022
Q2 		$125K Sell
671
-271
-29% -$25.9K 0.01% 502
2022
Q1 		$92K Hold
942
– – 0.01% 477
2021
Q4 		$154K Buy
+942
New +$207K 0.02% 509
2020
Q1 		– Sell
-183
Closed -$130K – 579
2019
Q4 		$130K Buy
+183
New +$126K 0.02% 376

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caxton Associates (New York)'s TCRT Position: Q2 2023 in Review

Caxton Associates (New York) sold out of Alaunos Therapeutics (TCRT) in Q2 2023, closing a stake of 1,909 shares — an estimated $180K sold.

Caxton Associates (New York) first reported a position in TCRT in Q4 2019 and held it in 7 quarters. The position peaked at $537K in Q3 2022. 100 funds tracked by Wall St. Rank hold TCRT as of Q2 2023.

  • Caxton Associates (New York) reported no remaining Alaunos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 1,909 Alaunos Therapeutics shares in Q2 2023, an estimated $180K.
  • Caxton Associates (New York) first reported a position in Alaunos Therapeutics in Q4 2019 and held it in 7 quarters.
  • Caxton Associates (New York)'s Alaunos Therapeutics position peaked at $537K in Q3 2022.
  • 100 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2023.

Based on Caxton Associates (New York)'s 13F filing for Q2 2023, filed 15 Aug 2023.